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ABSTRACT Chronic viral infections represent a major challenge to the host immune
response, and a unique network of immunological elements, including cytokines, are
required for their containment. By using a model persistent infection with the natu-
ral murine pathogen lymphocytic choriomeningitis virus clone 13 (LCMV Cl13) we in-
vestigated the role of one such cytokine, interleukin-27 (IL-27), in the control of
chronic infection. We found that IL-27 receptor (IL-27R) signaling promoted control
of LCMV Cl13 as early as days 1 and 5 after infection and that il27p28 transcripts
were rapidly elevated in multiple subsets of dendritic cells (DCs) and myeloid cells.
In particular, plasmacytoid DCs (pDCs), the most potent type 1 interferon (IFN-I)-
producing cells, significantly increased il27p28 in a Toll-like receptor 7 (TLR7)-
dependent fashion. Notably, mice deficient in an IL-27-specific receptor, WSX-1,
exhibited a pleiotropy of innate and adaptive immune alterations after chronic lym-
phocytic choriomeningitis virus (LCMV) infection, including compromised NK cell cy-
totoxicity and antibody responses. While, the majority of these immune alterations
appeared to be cell extrinsic, cell-intrinsic IL-27R was necessary to maintain early
pDC numbers, which, alongside lower IFN-I transcription in CD11b DCs and my-
eloid cells, may explain the compromised IFN-I elevation that we observed early af-
ter LCMV Cl13 infection in IL-27R-deficient mice. Together, these data highlight the
critical role of IL-27 in enabling optimal antiviral immunity early and late after infec-
tion with a systemic persistent virus and suggest that a previously unrecognized
positive-feedback loop mediated by IL-27 in pDCs might be involved in this process.
IMPORTANCE Persistently replicating pathogens, such as human immunodeficiency
virus, hepatitis B virus, and hepatitis C virus, represent major health problems world-
wide. These infections impose a long-term challenge on the host immune system,
which must be heavily and continuously regulated to keep pathogen replication in
check without causing fatal immunopathology. Using a persistently replicating ro-
dent pathogen, LCMV, in its natural host, we identified the cellular sources and ef-
fects of one important regulatory pathway, interleukin-27 receptor WSX-1 signaling,
that is required for both very early and late restriction of chronic (but not acute) in-
fection. We found that WSX-1 was necessary to promote innate immunity and the
development of aberrant adaptive immune responses. This not only highlights the
role of IL-27 receptor signaling in regulating distinct host responses that are known
to be necessary to control chronic infections, but also positions IL-27 as a potential
therapeutic target for their modulation.
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Chronic infections with persistently replicating viruses, which include the majorhuman pathogens human immunodeficiency virus type 1 (HIV-1), hepatitis C virus
(HCV), and hepatitis B virus (HBV), present the host with a lifelong challenge. As a
consequence, infection by these pathogens often results in heavily regulated immune
responses that aim to keep the persistent virus in check without causing fatal immu-
nopathology. Such immune regulation during chronic viral infections includes hypo-
functionality of CD4 and CD8 T cells and delayed antibody production, as well as
rapidly attenuated, but sustained, type I IFN (IFN-I) responses (reviewed in reference 1).
Lymphocytic choriomeningitis virus (LCMV) is a small, segmented RNA virus of the
family Arenaviridae that cause natural, vertically transmitted, persistent infections in
selected rodent hosts. LCMV has a strain-dependent capacity to cause either acute, e.g.,
LCMV Armstrong 53b (ARM), or chronic, e.g., LCMV clone 13 (Cl13), systemic infection
in adult mice (2). Chronic infection of mice with LCMV Cl13 results in a systemic
infectiont sharing many common immunological features with persistent human in-
fections, which is eventually cleared from the majority of tissues by 100 days postin-
fection (p.i.) (1). Clearance of LCMV Cl13 requires a combined effort of innate B and T
cell-mediated immunity, as defects in any of the arms of the immune system result in
lifelong viremia (3–5).
Cytokine signaling can play pivotal roles in both promoting viral persistence and
eventual control of LCMV. Increased signaling via interleukin-10 (IL-10) and transform-
ing growth factor beta (TGF-) has been described during chronic LCMV infection and
can dampen T cell responses (6–9). Exhausted virus-specific T cells also become less
responsive to the critical c survival cytokines IL-2, IL-7, and IL-15 (10–12), although
exogenous IL-2 and IL-7 can be used therapeutically to promote virus control in an
established LCMV Cl13 infection (10, 13). IL-21, another c cytokine, is crucial for
maintenance of virus-specific CD8 T cell numbers during LCMV Cl13 infection (14–16).
Meanwhile, IL-6 is critical for maintaining virus-specific CD4 T cell responses by
promoting T follicular helper cell (TFH) differentiation and virus-specific antibody (17).
The type I interferons IFN- and - are rapidly elevated and subsequently attenuated
after chronic LCMV infection, playing an important, though complex, role in direct viral
control and orchestration of immune responses (18–23).
IL-27 is a heterodimeric cytokine comprised of IL-27p28 and EBI3 subunits, making
it structurally related to the IL-12 family of cytokines (reviewed in reference 24). It
signals through the common IL-6 cytokine family signal transduction molecule gp130
in conjunction with a cytokine-specific receptor, WSX-1 (encoded by Il27ra). In accor-
dance with IL-27’s use of gp130, downstream signaling primarily occurs through
phosphorylation of STAT-1 and STAT-3, but IL-27 can also cause the phosphorylation of
STAT-2, -4, and -5 (25, 26). WSX-1 is highly expressed on T cells, and initial studies on
the biological role of IL-27 focused on CD4 and CD8 T cells (27). In vitro, IL-27 can
upregulate CD8 T cell expression of IFN- and granzyme B, enhancing cytotoxic
function (28), while on CD4 T cells, it promotes increased Tbet expression and T helper
1 (Th1) differentiation (26). In regulatory T cells (Tregs), IL-27 can regulate distinct
functional characteristics (29, 30), while in helper T cells it is also associated with the
production of IL-21 and suppression of Th17 responses (31–34). During peptide vacci-
nation, IL-27 can be important in the generation of TFHs (34). In contrast, IL-27 signaling
can also promote IL-10 production by CD4 T cells in vivo (35, 36), in part via upregu-
lation of Blimp-1, a transcriptional antagonist of TFH differentiation (37). IL-27 also
influences other immune cells, regulating natural killer (NK) cell cytotoxicity and
cytokine secretion (38); upregulating CD39 on conventional dendritic cells (DCs), which
results in enhanced suppression of T cell responses (39); and inhibiting viral replication
in HIV- and HCV-infected cells in vitro (40–42).
In contrast to their wild-type (WT) counterparts, WSX-1-deficient mice develop
lifelong viremia after LCMV Cl13 infection (43). While intrinsic WSX-1 signaling is
required for the optimal accumulation and maintenance of virus-specific CD4 T cells,
CD4 T cell-extrinsic mechanisms cause enhanced numbers of virus-specific CD4 T cells
in WSX-1-deficient mice infected with LCMV Cl13, suggesting additional mechanisms
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underlying the lack of virus control in nonchimeric mice (43). In this study, we found
that IL-27 expression was rapidly increased after LCMV Cl13 infection. Specifically, IL-27
was elevated in conventional DCs (cDCs), plasmacytoid DCs (pDCs), and macrophages,
and this was fully dependent on Toll-like receptor 7 (TLR7) in pDCs but TLR7 indepen-
dent in cDCs and macrophages. Loss of IL-27 signaling resulted in reduced IFN-I and
dysregulated DC and NK cell numbers and/or activation, which correlated with a
diminished capacity to control LCMV Cl13 early after infection. Although ubiquitous
WSX-1 deficiency led to enhanced virus-specific CD8 T cell and plasmablast numbers,
virus-specific antibody responses were diminished at later stages of infection, providing
a possible explanation for the failure to control persistent replication late after infec-
tion. Importantly, mixed chimeras indicated that, while most of the above-mentioned
immune alterations were cell extrinsic, IL-27 directly contributed to pDC accumulation
early after chronic LCMV infection. These results reveal a previously unappreciated role
for IL-27 in orchestrating early innate antiviral responses and late humoral immunity,
which are associated with very early and late containment of a systemic persistent
infection. In addition, our results suggest a novel DC positive-feedback loop, in which
viral infection rapidly promotes production of DC- and macrophage-derived IL-27,
directly promoting pDC accumulation and enhancing IFN-I transcription in cDCs early
after infection.
RESULTS
IL-27 promotes early control of LCMV clone 13 infection. We have previously
reported that WSX-1 is not only required for long-term control of LCMV Cl13, but also
seems to regulate the viral burden earlier in infection (43). In confirmation of this, we
found that Il27ra/ mice had significantly increased viremia at days 5, 9, and 11 p.i.
with LCMV Cl13 compared to WT mice, with similar viral loads seen at day 15 (Fig. 1A).
Importantly, in contrast, there was no apparent defect in the ability of Il27ra/ mice
to control LCMV ARM, with viremia being undetectable by day 11 p.i. Viral loads at time
points earlier than day 5 p.i. are difficult to determine, especially within the first 24 h
postinfection. The expression of both lcmv gp and np in spleen homogenates, however,
was elevated in the absence of WSX-1 24 h after LCMV Cl13 infection (Fig. 1B).
Taken together, these data showed that IL-27 signaling was critical in promoting
persistent virus control from a very early time point p.i. and appeared essential for
long-term control of persistent (but not acute) LCMV infection (Fig. 1A) (43).
Systemic viral infection rapidly induces IL-27 upregulation. Viral infection often
results in the rapid production and release of many cytokines and chemokines, which
prime and instruct the immune system. Many of these mediators are quickly damp-
ened, while others are produced at heightened concentrations throughout infection or
undergo several phases of production (17). Given that IL-27 signaling is crucial to
FIG 1 Il27ra/ mice had increased viral loads early after chronic, but not acute, LCMV infection. WT and Il27ra/
mice were infected with 2  106 PFU of LCMV Cl13 i.v. (A) Serum viral loads were determined at multiple times
postinfection and compared with those of WT and Il27ra/ mice infected with 2  106 PFU LCMV Arm i.v. ffu,
focus-forming units. The data represent the results of 2 independent experiments; n  10 mice per time point per
group. (B) lcmv gp and np expression levels were determined in the spleen homogenates of LCMV Cl13-infected
WT and Il27ra/mice 24 h postinfection. The data are representative of the results of 2 independent experiments;
n  5 mice per group; d.p.i., days p.i. The error bars indicate SEM. n.d., not determined. ***, P  0.001; **, P  0.01;
*, P  0.05.
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contain the magnitude of early LCMV Cl13 replication (Fig. 1A and B), we sought to
determine the timing and cellular source of IL-27 production early during LCMV Cl13
infection.
IL-27 was undetectable in the serum at any time point analyzed (between day 1 and
day 30 postinfection) after LCMV Cl13 infection (data not shown). Uninfected WT
C57B/6 mice, however, did have detectable levels of IL-27 in whole spleens, which were
increased at day 1 p.i. and returned to basal naive concentrations at days 8 and 25 p.i.
(Fig. 2A). Expression of Il27p28 transcript in the whole spleen mirrored the protein, with
detectable transcripts in naive mice and significant increase at day 1, but not days 8 and
25, p.i. In contrast, splenic Ebi3 expression was unchanged throughout infection or
slightly reduced at day 25 p.i. (Fig. 2B).
Having determined that IL-27 was elevated rapidly upon infection, we next inves-
tigated which cells might be responsible for its production. CD8 DCs and macro-
phages have previously been reported to produce significant amounts of IL-27 (44, 45).
As DCs and macrophages are highly activated in response to LCMV (22), we analyzed
IL-27 production by these cells after LCMV infection, gating CD8 DCs, CD11b DCs,
pDCs, and CD11c CD11b cells (here referred to as myeloid cells; all the cell popu-
lations were gated as shown in Fig. 3E). There was detectable Il27p28 expression in DC
and myeloid subsets prior to infection, which was highly upregulated in the same cells
24 h p.i. (Fig. 2C). Across the 4 independent experiments analyzed, however, it was
unclear if any single cell type upregulated Il27p28 significantly above the other cell
types, suggesting upregulation was similar in all the cell types. In contrast Ebi3
expression was not dramatically upregulated after infection. Similar patterns of Il27p28
FIG 2 Dendritic cells and other myeloid cells were major producers of IL-27 within 24 h after LCMV infection in vivo. (A and B) Wild-type C57B/6 mice
were infected with 2 106 PFU of LCMV Cl13 i.v., and the concentration of IL-27p28 (A) and expression of Il27p28 and Ebi3 (B) were determined in spleen
homogenates at days 1, 8, and 25 p.i. and compared to the levels in uninfected (unif) mice. (C) WT mice were infected with LCMV Cl13 or Arm 53b, and
expression of Il27p28 and Ebi3 relative to Gapdh was determined in FACS-purified splenic pDCs (CD19 Thy1.2 NK1.1 CD11c CD11b B220 PDCA1),
CD8 DCs (CD19 Thy1.2 NK1.1 CD11b B220 CD8 CD11c), CD11b DCs (CD19 Thy1.2 NK1.1 CD8 CD11b CD11c), and myeloid cells
(CD19 Thy1.2 NK1.1 CD11c CD11b). (D) Il27p28 and Ebi3 expression and IL27p28 protein levels were determined by quantitative PCR (qPCR) and
by ELISA, respectively, in TLR agonist-stimulated DCs from BM-Flt3L cultures. (E) Expression of Il27p28 and Ebi3 determined as for panel C with WT or
Tlr7/ mice at day 1 after LCMV Cl13 infection. The data are representative of the results of 3 (A and B) or 2 (D and E) independent experiments with
3 mice per group or cumulative for 4 independent repeats with 5 mice (C) The error bars indicate SEM. ***, P  0.001; **, P  0.01; *, P  0.05.
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FIG 3 IL-27 regulates IFN-I and DC responses after LCMV infection. WT or Il27ra/ mice were infected with 2  106 PFU of LCMV ARM or Cl13 (A) or
left uninfected (A to G) and analyzed 24 h p.i. (A) Serum IFN-I measured by bioassay. (B) Ifna4, -6, and -7 and Ifnb expression measured in spleen
homogenates. (C) Serum IL-6 and TNF measured by ELISA. (D) Il6, Tnf, Il18, and Il12p35 expression in spleen homogenates. (E) Number of splenic DCs
determined by FACS. (F) Ifna and Ifnb expression determined in FACS-isolated DCs. (G) CD86 expression in DC subsets determined by flow cytometry.
The data represent the results of 3 experiments with 4 mice per group. The error bars indicate SEM. **, P  0.01; *, P  0.05.
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elevation were seen in mice infected with the acute LCMV ARM at day 1 p.i. Interest-
ingly, however, by day 8 postinfection, Il27p28 expression was still increased in pDCs
isolated from Cl13-infected, but not ARM-infected, mice. None of the other cell types
examined showed increased Il27p28 expression at the later time point in either infec-
tion.
Given that DCs rapidly produce IL-27 in response to LCMV infection in vivo, we next
evaluated whether this could be TLR mediated. Flt3L differentiated bone marrow (BM)
DCs, a mixture of pDCs and CD11b DCs, showed rapid upregulation of Il27p28 and
Ebi3 in response to TLR7 (loxoribine) or TLR9 (CpG) agonists and to a lesser extent or
not at all upon TLR4 (lipopolysaccharide [LPS]) stimulation (Fig. 2D). They did not
respond to poly(I·C), a TLR3 agonist. Loxoribine, CpG, and LPS, but not poly(I·C),
stimulation also led to detectable IL-27 protein in the culture supernatants (Fig. 2D). As
pDCs had not previously been reported to produce IL-27 and had prolonged IL-27
expression after LCMV Cl13 infection, we evaluated whether TLR7 signaling, known to
be essential for pDC IFN-I production during LCMV infection (22), played a role in the
in vivo production of IL-27. Indeed, Il27p28 and Ebi3 upregulation was completely
ablated in pDCs taken from Tlr7/ LCMV-infected animals (Fig. 2E). TLR7 deficiency did
not, however, affect IL-27 expression by the other DC or myeloid cell types analyzed.
Taken together, these data indicated that IL-27 was produced by various innate
cellular sources early after LCMV infection, and this elevation was mostly transient in
DCs and macrophages but more sustained in pDCs after persistent LCMV infection. In
particular, pDC (but not cDC) production of IL-27 was fully dependent on TLR7.
IL-27 regulates early innate immune responses after LCMV infection. LCMV
infection results in rapid activation of the host’s immune response, including produc-
tion of high levels of IFN-I (22). Early IFN-I signaling can be vital in establishing an
antiviral environment early during infection by the induction of gene networks known
to perturb viral replication and to activate a range of immune cells (46). Compared to
WT mice, Il27ra/ mice had significantly lower circulating bioactive IFN-I 24 h after
infection with LCMV ARM or Cl13 (Fig. 3A). Absence of WSX-1 also resulted in failure to
upregulate both Ifna and Ifnb in the spleen after LCMV Cl13 infection (Fig. 3B). In
contrast, the proinflammatory mediators IL-6 and tumor necrosis factor (TNF) were both
significantly increased in sera from Il27ra/ versus wild-type mice 24 h after Cl13
infection (Fig. 3C). Il6, Tnf, and Il18 expression was also significantly higher in the
spleens of Il27ra/ mice than in those of WT controls, but expression levels of Il12p35
were similar in WT and WSX-1-deficient mice (Fig. 3D).
In LCMV infection, IFN-I is produced by both pDCs, via a TLR7-dependent pathway,
and cDCs and macrophages, where production is dependent on MAVS and MDA5 (22,
47, 48). Uninfected Il27ra/ mice had numbers of pDCs, cDCs, and other myeloid cells
similar to those of WT mice in the spleen (Fig. 3E). The numbers of CD8 DCs, CD11b
DCs, and CD11c CD11b myeloid cells in the spleen 24 h after infection were
unaffected by Il27ra deletion; however, the number of pDCs at this time was signifi-
cantly reduced, by approximately 2-fold, in Il27ra/ mice compared to WT mice (Fig.
3E). Expression of IFN-I genes by the different cell populations was variably affected by
the absence of WSX-1. Other myeloid cells had significantly reduced Ifna, and CD11b
DCs had significantly reduced Ifna and Ifnb expression, but CD8 DCs had increased
Ifnb expression (Fig. 3F). Meanwhile, Ifna and Ifnb expression by pDCs, which had the
highest expression of both IFN-I genes on a per cell basis (22), was unaffected by WSX-1
deletion (Fig. 3F). In addition, upregulation of the costimulatory molecule CD86 was
adversely affected in all four innate cell populations (Fig. 3G).
NK cells, responding to changes in the cytokine milieu, also promptly respond to
LCMV infection. The numbers of NK cells in the spleen both prior to and 24 h after
infection were unaffected by the deletion of Il27ra (Fig. 4A). Interestingly, however, the
functionality of NK cells 24 h after LCMV Cl13 infection was altered, with Il27ra-/ NK
cells showing reduced granzyme B and increased IFN- production compared to WT NK
cells (Fig. 4B). Specifically, it appeared from the gating that the proportion of granzyme
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B-positive Il27ra/ NK cells was similar to that seen in WT NK cells (data not shown),
but the per cell expression of granzyme B in granzyme B-positive NK cells was
significantly lower (Fig. 4B). Likewise, while there was a small increase in the proportion
of IFN- NK cells in Il27ra/ mice compared to WT mice, the biggest change was the
overall amount of IFN- per NK cell (Fig. 4B). Surprisingly, given the increased IFN-
production, NK cells from Il27ra/ mice had decreased Tbet, a known positive
regulator of IFN- production, compared to WT mice (Fig. 4C). This was accompanied
by reduced degranulation, as measured by LAMP-1 (Fig. 4D).
These data showed that signaling through IL-27 regulated a number of critical
innate immune parameters very early after systemic LCMV infection. These changes
should, however, be considered in the light of the increased viral RNA (Fig. 1B),
suggesting more viral replication, which could impact the degree of stimulation or
inhibition of a particular pathway in cells from Il27ra/ virus- versus WT-virus-infected
mice.
Direct IL-27 signaling favors pDC accumulation early after LCMV Cl13 infection.
To dissect IL-27-mediated restriction of viral replication that subsequently impacts
innate cell numbers and function versus direct regulation of innate cells by IL-27, we
first investigated a putative role of IL-27 in directly controlling LCMV growth indepen-
dently of innate immune cells. Pretreatment of LCMV-susceptible cells (i.e., A549 cells)
with increasing doses of recombinant IL-27 (rIL-27) before LCMV Cl13 infection had no
effect on viral replication (Fig. 5A). This suggested that IL-27 could not increase an
antiviral state in LCMV-susceptible cells and that the enhanced viral growth early after
chronic LCMV infection was unlikely to have been a consequence of cell-intrinsic
defective virus control in infected cells and may instead have resulted from the
above-mentioned altered innate cell responses.
To further discern cell-intrinsic versus cell-extrinsic innate cell defects in the absence
of il27ra signaling, we generated CD45.1:Il27ra/ and CD45.1:C57BL/6 WT mixed bone
FIG 4 IL-27R signaling regulates NK cell function after LCMV infection. WT and Il27ra/ mice were infected with 2  106 PFU of LCMV
Cl13 i.v., analyzed at 24 h p.i. (D1), and compared to uninfected mice (U). Spleen NK cells (NK1.1 CD3 CD19) were enumerated by flow
cytometry (A), along with their expression of granzyme B (GrzB) and IFN- (B), Tbet (C), and LAMP-1 (D). Granzyme B, IFN-, and LAMP-1
were measured after incubation of splenocytes in the presence of brefeldin A for 5 h. The data are representative of 3 experiments with
4 mice per group. The error bars indicate SEM. **, P  0.01; *, P  0.05.
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marrow chimeras and analyzed DCs and NK cells 24 h after LCMV Cl13 infection.
Il27ra/ cDCs were slightly reduced in frequency compared to both cDCs from the
CD45.1 compartment and CD45.2 DCs from control chimeras (Fig. 5B), but this was
not observed in nonchimeric Il27ra/mice (Fig. 3E). In contrast, the more pronounced
intrinsic defect in the numbers of Il27ra/ pDCs 24 h after LCMV Cl13 infection than
in WT pDCs (Fig. 5C) was in agreement with the reduced pDC accumulation observed
in the Il27ra/mice 1 day p.i. (Fig. 3E). CD86 expression by both pDCs and cDCs, which
we had seen decreased in nonchimeric WSX-1-deficient mice (Fig. 3G), was actually
significantly increased in Il27ra/mice compared to their CD45.1WT counterparts in
FIG 5 IL-27 has no direct antiviral effect, and extrinsic Il27ra signaling promotes optimal NK cell and DC activation after LCMV Cl13 infection. (A) A549
cells were infected at an MOI of 0.05 or 0.5 with LCMV Cl13 with or without treatment with increasing doses rIL-27 from 1 h prior to infection. Lcmv gp
expression was determined by RT-qPCR. (B to D) WT:C57BL/6 or WT:Il27ra/ mixed bone marrow chimeras were infected with 2  106 PFU LCMV Cl13
i.v. or left uninfected, and 24 h p.i., the spleens were analyzed for the frequency of cDCs (CD11b DCs) (B), the frequency of pDCs (C), and CD86 expression
by cDCs and pDCs (D). (E) Frequency and IFN-, Tbet, and granzyme B expression of NK cells. (F and G) Flt3L-derived BM DCs were stimulated with
loxoribine in the presence or absence of 50 ng/ml rIL-27. The data represent 4 mice per condition from 2 independent experiments (A); 6 uninfected
controls, 5 uninfected Il27ra/ chimeras, 4 infected controls, and 8 infected Il27ra/ chimeras from 2 independent experiments (B to E); and 3 cultures
per condition representative of the results of 3 independent experiments (F and G). The error bars indicate SEM. **, P  0.01; *, P  0.05.
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bone marrow chimeras, but this effect was also observed in the CD45.1:WT control
chimeras (Fig. 5D). Intrinsic IL-27R signaling appeared to have no role in controlling NK
cell frequency or function, as measured by expression of Tbet, IFN-, and granzyme B
at day 1 after LCMV Cl13 infection (Fig. 5E). None of the above-mentioned DC or NK cell
phenotypes appeared to be affected in Il27ra/ versus WT cells before infection (Fig.
5B to E).
Given the above-mentioned cell-intrinsic effect of IL-27 in pDCs, we next investi-
gated the direct effect of recombinant IL-27 on uninfected BM-Flt3L-derived DCs (which
include pDCs) in the absence or in the presence of the TLR7 ligand loxoribine,
independently of the infectious environment. Under these conditions, we could not
detect any effect of recombinant IL-27 on either unstimulated or TLR-7-stimulated pDC
viability or numbers (Fig. 5F and data not shown), suggesting that the cell-intrinsic IL-27
induction of pDC maintenance observed in vivo may result from modulation of regu-
latory mechanisms that are not recapitulated in BM-derived pDCs. Furthermore, addi-
tion of rIL-27 to BM-derived DCs stimulated with loxoribine did not significantly affect
IFN-I production, with only a slight increase reaching statistical significance compared
to controls in 1 out of 3 independent experiments (Fig. 5G). Note that upon loxoribine
stimulation, only BM-derived pDCs, but not BM-derived cDCs, produced IFN-I (data not
shown).
Overall, these data showed that the majority of early defects seen in the innate
immune responses in the global absence of WSX-1 after LCMV Cl13 were cell extrinsic.
The exception was the effect on pDCs, which required IL-27 signaling to optimally
maintain their numbers early after infection.
Il27ra shapes the adaptive immune response to chronic LCMV. Containment of
persistent LCMV variants requires a combination of innate, CD8, and CD4 T cells and
antibody-mediated immunity, as impairment of any one of these compartments can
allow virus to persist indefinitely (3–5, 49). Given that early innate immune responses
are crucial to prime and sustain the adaptive response to infection and the prior
observation that late control of LCMV Cl13 persistence is WSX-1 dependent (43), we
next sought to determine the effect of Il27ra deletion on the generation of LCMV-
specific T cell and B cell responses.
IL-27 has been implicated in the proliferation and differentiation of antigen-specific
CD8 T cell responses (28, 50, 51). Il27ra/ mice had significantly fewer DbGP276–284
CD8 T cells than WT mice. In the spleen, there were significantly increased numbers
of DbNP396–404 and DbGP33–41 CD8 T cells at day 9 p.i. in the absence of WSX-1
(Fig. 6A). By day 30 p.i., however, the numbers of LCMV-specific CD8 T cells were similar
in WT and knockout (KO) mice. Il27ra/ mice also had slightly increased numbers of
blood LCMV-specific DbNP396–404 and DbGP276–284 CD8 T cells at days 9 and 15 p.i.,
but these differences did not reach statistical significance (Fig. 6B). The differences
declined as the infection progressed, and by day 45 p.i., Il27ra/ mice had fewer
circulating GP276–284-specific CD8 T cells than WT mice. The functional capacities of
GP33–41-stimulated CD8 T cells to hierarchically produce IFN-, TNF, and IL-2 were
similar in WT and Il27ra/ mice at both days 9 and 30 p.i. (Fig. 6C). Despite this, PD-1
expression, a key marker of T cell exhaustion during chronic infection, by virus-specific
CD8 T cells was significantly lower in the absence of WSX-1 at day 9 p.i. and trended
the same way at day 30 p.i. (Fig. 6D). In comparison to chronic LCMV infection, during
acute LCMV infection, circulating DbNP396–404 CD8 T cell numbers were similar in
WT and Il27ra/ mice throughout infection; however, DbGP33–41 numbers were
elevated in the absence of WSX-1 (Fig. 6E).
Gp130 on virus-specific CD4 T cells is required for their survival and differen-
tiation into TFHs during LCMV ARM or Cl13 infection under competitive conditions
(43, 52). In Il27ra/ mice, however, the number of virus-specific CD4 T cells was
actually heightened at day 9 after LCMV Cl13 infection, though it returned to
numbers similar to those of WT mice at day 30 p.i. (43). One remaining question
from these studies was whether IL-27, given its importance in determining CD4 T
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cell differentiation in other inflammatory and infectious environments (32, 34),
regulated CD4 T cell fate during LCMV infection. Neither TFH nor Treg frequencies
were affected by WSX-1 deletion at days 9 and 30 after LCMV Cl13 infection (Fig. 6F
and G). At the same times, secretion levels of IFN-, TNF, and IL-21, a key antiviral
FIG 6 IL-27 signaling has limited effects on T cell responses during LCMV infection. WT and Il27ra/ mice were used throughout. (A to D) The numbers
of splenic DbNP396–404 and DbGP33–41 CD8 T cells (A), the numbers of circulating DbNP396–404 and DbGP276–284 CD8 T cells (B), cytokine secretion
by splenic CD8 T cells after ex vivo GP33–41 peptide stimulation (C), and PD-1 expression by splenic DbGP33–41 CD8 T cells after LCMV Cl13 infection
(D) were determined by flow cytometry. (E) Frequencies of DbNP396–404 and DbGP33–41 CD8 T cells in the blood determined after infection with
2  106 PFU of LCMV ARM i.v. (F to H) Frequencies of TFHs, gated as CXCR5 ICOS SLAM CD4 cells (F), Foxp3 CD4 T cells (G), and cytokine-secreting
CD4 T cells (H), in response to GP67–77 peptide stimulation determined in the spleens of LCMV Cl13-infected mice. The data represent 4 mice per group
and are representative of the results of at least 2 independent repeats. The error bars indicate SEM. ***, P  0.001; **, P  0.01; *, P  0.05.
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cytokine and potential downstream target of IL-27, by virus-specific CD4 T cells
were all similar (Fig. 6H).
Virus-specific antibody responses are also vital for containment of chronic LCMV
infection (5). Germinal center (GC) B cell numbers were similar in WT and WSX-1-
deficient mice at days 9 and 30 after LCMV Cl13 infection (Fig. 7A). However, Il27ra/
mice did have a population of B cells that were CD38 GL7 in their spleens at day 9
p.i. that was not observed in WT mice. Further evaluation of B cell subsets revealed that
the cells represented a subset of CD138 B cells and that Il27ra/ mice had signifi-
cantly more of these IgD plasmablasts than WT mice at day 9 postinfection (Fig. 7B).
Perhaps counterintuitively, given the larger number of plasmablasts, Il27ra/ mice
had slightly reduced LCMV-specific IgG by day 30 p.i., and absence of IL-27R led to
deficiencies in both LCMV-specific IgG2a and IgG1 (Fig. 7C) and slightly affected IgG
avidity at day 30 p.i., although it was similar to that seen in WT mice by day 60 (Fig. 7D).
Loss of IL-27R signaling did not affect the amount, type, or quality of antibodies
produced in response to acute LCMV ARM infection, nor was antibody induction on
rechallenge with LCMV Cl13 affected (Fig. 7E and F).
To determine if the changes in the adaptive immune response in the absence of
Il27ra were a result of the altered viral and inflammatory environment or of direct
signaling on B and T cells, we next analyzed responses in mixed bone marrow chimeras.
FIG 7 IL-27 deficiency results in reduced antibody responses in chronic, but not acute, infection. (A to D) WT and Il27ra/ mice were infected with
2  106 PFU of LCMV Cl13 i.v., and the number of germinal center B cells (A); the number of CD138 plasmablasts at day 9 p.i. (B); LCMV-specific IgG,
IgG2a/c, and IgG1 (C); and IgG avidity (D) were measured in the sera. (E) WT and Il27ra/ mice were infected with 2  106 PFU of LCMV ARM i.v., and
levels of serum LCMV-specific IgG2a and IgG1 were determined before and after rechallenge with LCMV Cl13. (F) Avidity of LCMV-specific IgG in serum.
The data are representative of the results of 2 independent experiments on 4 mice per time point per group. The error bars indicate SEM. **, P  0.01;
*, P  0.05.
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In contrast to the cell-intrinsic IL-27R regulation of LCMV-specific CD4 T cell numbers
late after LCMV Cl13 infection (43), we observed that there were similar frequencies of
both virus-specific CD8 T cells and their PD-1 expression in the WT and Il27ra/
compartments of CD45.1:Il27ra/ mixed BM chimeras at both days 9 and 30 after
LCMV Cl13 infection (Fig. 8A). We also saw no significant difference in GC B cell or
plasmablast frequencies at either time point p.i. (Fig. 8B and C).
Together, these data showed that IL-27 signaling affected adaptive responses by
decreasing virus-specific antibody responses despite increasing the numbers of virus-
specific CD8 T cells and plasmablasts. Notably, only from day 30 p.i. onward, when viral
loads were once again significantly different in WT and Il27ra/ mice (43), did
virus-specific antibodies begin to become adversely affected. Importantly, similar de-
fects were not seen in the generation of immunity against LCMV ARM, and when
wild-type and Il27ra/ GC B cells and plasmablasts were in the same environment,
their frequencies were comparable. Although there may be some IL-27 intrinsic effects
on parameters not studied here, our data suggested that the environment induced by
IL-27R signaling is likely a key driver of antibody induction during chronic LCMV
infection. Even if B cell extrinsic, however, the above-mentioned defective antibody
responses could contribute to the inability of Il27ra/ mice to clear LCMV Cl13
infection.
DISCUSSION
Containment of continuously replicating chronic viral infections requires a com-
bined effort of innate cells, T cells, and antibodies (1). Here, we found that during
chronic LCMV infection, IL-27 deficiency was associated with dysregulation of the
innate immune response and failure to contain early viral replication. IL-27 was en-
hanced rapidly by DCs and other myeloid cells upon infection, with pDCs in particular
upregulating IL-27 transcripts in a TLR7-dependent fashion. Early IL-27 signaling aided
in promoting peak IFN-I elevation, the NK cell cytotoxic program, and DC activation.
FIG 8 Intrinsic IL-27 signaling is not required for CD8 T cell or B cell differentiation. WT:Il27ra/ mixed
bone marrow chimeras were infected with 2  106 PFU LCMV Cl13 i.v., and at days 9 and 30 p.i., the
frequencies of DbGP33–41 CD8 T cells and their PD-1 expression (A), GL7 CD38 germinal center B
cells (B), and IgDCD138 plasmablasts (C) in the WT (CD45.1) and Il27ra/ (CD45.2) spleen
compartments were determined. The data represent 7 mice from 3 independent experiments.
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This aberrant inflammatory response was associated with disrupted adaptive immune
responses at later stages of infection and lifelong viremia (43).
IL-27 signaling has a well-described role in T cell responses, where it regulates both
the differentiation and function of CD4 and CD8 T cells, in particular promoting Tbet
and IFN- production (25, 26, 28). IL-27 can also play a critical immunoregulatory role,
suppressing IL-2 production by CD4 T cells (53) and promoting their IL-10 production
(35–37). In accordance with this, IL-27R signaling has a negative impact on immune
protection after chronic infections, such as Mycobacterium tuberculosis or murine
cytomegalovirus (54, 55). In contrast, we have previously shown that IL-27R signaling is
critical for promoting immune protection during chronic LCMV infection, where cell-
intrinsic IL-27R signaling promotes the survival of virus-specific CD4 T cells when
IL-27R-deficient and -sufficient CD4 T cells are placed in competition (43). Notably,
ubiquitous IL-27R signaling deficiency resulted in increased numbers of virus-specific
CD4 T cells at day 9 p.i. (43), but here, we show that it did not affect their cytokine
secretion, TFH differentiation, or the frequency of Foxp3 regulatory T cells, which IL-27
can modulate under different conditions (34, 43). Global loss of IL-27R signaling also
increases the number of LCMV-specific CD8 T cells after both chronic and acute
infection, but as with the increase in CD4 T cell numbers, this is not a cell-intrinsic effect,
and loss of IL-27R does not adversely affect the functional capacity of the CD8 T cell
response. Although further studies may reveal additional IL-27 effects on T cells, our
work highlights selected cell-intrinsic versus -extrinsic, as well as context-specific, roles
of IL-27R signaling on T cell responses to a systemic persistent pathogen.
While we did not observe major alterations in T cell responses from WSX1-deficient
mice by day 30 p.i., prior to the establishment of lifelong viral infection, there were
more notable reductions in the quantity and quality of LCMV-specific antibodies. We
and others have previously reported that antibody responses are critical for the control
of chronic LCMV infection (5, 17, 56). IL-27 has been shown to influence TFH formation
and function in certain circumstances (34, 43), and it can also act directly on B cells. In
human B cell cultures, IL-27 signaling has the capacity to regulate the proliferation of
naive B cells, their differentiation into plasma cells, and isotype switch (57, 58), while in
similar cultures using murine B cells, it was found to upregulate Tbet and promote
IgG2a switch (59). In chronic LCMV infection, IL-27 signaling does not appear to
diminish GC B cell differentiation, although it does limit the emergence of plasmablasts.
Importantly, however, during LCMV Cl13 infection, IL-27 limited the production of
LCMV-specific IgG2a and IgG1, along with overall IgG avidity. IL-27 signaling did not
affect either the production or type of antibodies after acute LCMV infection, where
viral clearance is maintained in the absence of IL-27, nor does cell-intrinsic IL-27
signaling appear to be important for GC B cell or plasmablast numbers. Taken together,
our data show that intrinsic IL-27R signaling has modest effects on the outcome of
multiple aspects of adaptive immune responses studied here. It is therefore likely that
the reduced levels of LCMV-specific IgGs seen in chronically infected Il27ra/ mice
resulted, at least in part, from their increased viral loads and inflammatory state.
Crucially, there were significant effects on the innate inflammatory response in the
absence of IL-27 signaling. Notably, IFN-I production, which peaks 24 h after LCMV
infection (21), was significantly reduced in the absence of IL-27 signaling. IFN-I pro-
motes an antiviral state in cells through the induction of hundreds of interferon-
stimulated genes (ISGs) via phosphorylation of STAT-1 and STAT-2 (46). A reduction in
this process would explain the reduced virus control seen at early time points after
LCMV Cl13 infection, and it is possible that high viral loads at early time points
contribute to viral persistence at later stages. Signaling through IFN-R is critical for
control of LCMV Cl13 persistence, and its absence results in enhanced depletion and
exhaustion of virus-specific T cells (49), though sustained IFN-I signaling also has a
deleterious effect on T cell responses (18, 19). Thus, it is conceivable that reduced IFN-I
levels in Il27ra/ mice early after LCMV Cl13 infection could contribute to failure of
virus control at later points postinfection. In this study, we did not evaluate whether
IL-27R signaling influences chronic IFN-I signaling, as well. An alternative option is that
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IL-27 itself may drive a cell-intrinsic antiviral state that protects mice from LCMV
infection. IL-27 can phosphorylate STAT-1 (25, 42) and has been shown to have antiviral
activity against other persistent viral infections, including both HIV and hepatitis C virus
(41, 42). During HIV infection, this process is related to IL-27’s ability to upregulate a
subset of ISGs independently of IFN-I (41) and to promote a number of anti-HIV
molecules (60, 61); however, we show here that, at least when used in vitro, IL-27
appears to have no restrictive effect in LCMV growth, making this hypothesis less likely.
Interestingly, however, IFN-I itself is also capable of driving IL-27-induced antiviral
activity (62). During LCMV infection, IL-27 is produced by pDCs, cDCs, and other
myeloid cells, the same cells reported to produce the majority of IFN-I (47, 48), and
indeed, pDCs require TLR7 to produce both IFN-I (22) and IL-27. Furthermore, CD11b
DCs and other CD11b myeloid cells from Il27ra/ mice had reduced Ifna and Ifnb
transcription, while intrinsic WSX-1 signaling after LCMV Cl13 infection was also critical
for maintenance of pDCs, which are major sources of IFN-I in vivo (22). Taken together,
these findings suggest that an IL-27 positive-feedback loop may contribute to main-
tenance of pDC numbers very early after infection and to IFN-I production from myeloid
cells and that disabling such a loop could compromise peak IFN-I responses and virus
control.
IL-27 deficiency also affected NK cell and DC activities. The consequences of
compromised DC maturation in the absence of IL27R signaling early after chronic LCMV
infection are difficult to dissect, given that IL-27R-deficient mice also had heightened
antigen burdens at these early time points. On the other hand, IL-27 can enhance NK
cell antitumor activity, including upregulation of Tbet and granzyme B in vivo (38), both
of which we found to require IL-27 for optimal upregulation after LCMV Cl13 infection.
One surprising observation was that, in the absence of global IL-27R signaling, IFN-
production by NK cells increased, but Tbet expression decreased. The IFN- gene is a
target of Tbet in NK cells, and IFN- and Tbet are commonly induced by the same
stimuli, although Tbet is not an absolute requirement for IFN- production by NK cells
(63). In human NK cells, IL-27 can directly upregulate Tbet in NK cells, as it does in T cells
(64); however, in vivo, there is a suggestion that IL-27 acts indirectly to promote NK cell
activity (65). One hypothesis is that Eomes, another key regulator of NK cell function
(66), compensates for the slightly lower expression of Tbet in the absence of IL-27R.
Critically, however, Il27ra/ NK cells displayed none of the defects found in IL-27R-
deficient animals when they were placed in the same environment as WT NK cells,
showing that none of the defects observed in NK cells are the result of direct IL-27
signaling. One mechanism by which NK cell activity could be modulated is through
promotion of IL-12 production by DCs; however, we found no difference in the levels
of Il12p35 in the spleen. However, we did find higher expression of Il18 in Il27ra/
mice, and IFN- production by NK cells is known to be heavily induced by IL-18,
synergistically with IL-12 (67, 68), which may explain the heightened IFN- production
by NK cells from IL-27R-deficient infected mice. NK cell activity is traditionally consid-
ered to be antiviral (reviewed in reference 69). During chronic infection with LCMV,
however, the dominant role of NK cells appears to be in curbing virus-specific T cell
responses and preventing the development of immunopathology, rather than reducing
the viral load (70, 71). Thus, the reduced NK cell cytotoxic program may also help
explain the increased numbers of virus-specific CD8 and CD4 T cells that we
observed in IL-27R-deficient mice.
In conclusion, our study demonstrated that ubiquitous IL-27R deficiency affected
antiviral immunity at multiple junctures during a systemic chronic viral infection in vivo.
In contrast to previous studies that focused on IL-27’s ability to regulate T cells, we
report here that IL-27R signaling largely influenced innate immunity and altered the
inflammatory environment after infection, likely influencing long-term immunity. This
was associated with IL-27’s ability to promote very early, as well as late, pathogen
containment during chronic viral infection.
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MATERIALS AND METHODS
Mice and viral stocks. WT C57BL/6, WT CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ), and Il27ra/ (WSX-1-
deficient) mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Tlr7/ mice were kindly
provided by Shizuo Akira (Osaka University, Osaka, Japan). For mixed bone marrow chimeras, recipient
mice received 1,000 rads and were reconstituted with 5.0 106 (at a 50:50 ratio between the two donors)
bone marrow cells intravenously (i.v.) The chimeras were then allowed to reconstitute for 8 weeks prior
to infection. Mice were bred and maintained in a closed breeding facility, and mouse handling
conformed to the requirements of the National Institutes of Health and the Institutional Animal Care and
Use Guidelines of the University of California San Diego (UCSD). Unless otherwise stated, 6- to 8-week-old
mice were infected i.v. with 2  106 PFU of LCMV ARM or Cl13. Viruses were grown, identified, and
quantified as described previously (2, 72).
Purification of DCs. Spleens were incubated with 1 mg/ml collagenase D for 20 min at 37°C and
passed through a 100-m strainer to achieve a single-cell suspension. Splenocytes were then incubated
for 30 min with rat monoclonal antibodies (MAbs) specific for Thy1.2 and CD19, followed by magnetic
cell sorting using anti-rat immunoglobulin-coated magnetic beads (Qiamag beads; Qiagen, Redwood City,
CA) according to the manufacturer’s instructions. The bead-negative fraction of cells were then stained with
a panel of fluorescently conjugated MAbs, along with propidium iodide (PI), and fluorescence-
activated cell sorting (FACS) purified using a BD ARIA II (BD) for pDCs (PI CD11cintermediate/dim CD11b
B220 PDCA), CD11b cDCs (PI CD11c B220 CD11b CD8), CD8 DCs (PI CD11c B220
CD11b CD8), and other myeloid cells (PI CD11b CD11c) after B (CD19), T (Thy1.2), and NK (Nk1.1)
cell exclusion. Purities were 92%.
Flow cytometry. Flow cytometry was carried out as described previously (43). All antibodies and
tetramers used for T cell identification and functional characterization were also identical to those used
previously (43). Tetramers or monomers were kindly provided by the NIH Tetramer Core Facility (Atlanta,
GA). For DCs and macrophages, the following anti-mouse antibodies (from eBioscience unless otherwise
stated) were used: anti-Thy 1.2-peridinin chlorophyll protein (PerCP)-Cy5.5 (145-2C11), CD19-PerCP-Cy5.5
(eBio1D3), NK1.1-PerCP-Cy5.5 (PK136), CD11b-phycoerythrin (PE)-Cy7 (M1/70), B220-allophycocyanin
(APC)-eF780 (RA3-6B2), PDCA-1-fluorescein isothiocyanate (FITC) (eBio927), CD86-PE (IT2.2; Biolegend),
and CD8-eF450 (53-6.7). For NK cell identification, freshly isolated splenocytes were surface stained with
anti-NK1.1-PerCP-Cy5.5 (PK136) and CD3e-eFluor450 (17A2). For Tbet analysis, the cells were then stained
intranuclearly with anti-mouse/human-Tbet-FITC (4B10; Santa Cruz Biotech, Dallas, TX) after fixation with
the Foxp3 permeabilization and fixation kit (eBioscience). For granzyme B, Lamp-1, and IFN- staining,
splenocytes were incubated for 5 h at 37°C in the presence of 1 g/ml brefeldin A and anti-mouse
CD107a/b-FITC (1D4B, Invitrogen). NK cells were stained and fixed with 1% paraformaldehyde and
permeabilized with saponin. Subsequently, they were stained with IFN-–APC (XMG1.2) and anti-human
granzyme-B–PE (GB12; Invitrogen). Cells were acquired using the Digital LSR II flow cytometer (Becton
Dickinson, San Jose, CA). Flow cytometric data were analyzed with FlowJo software (TreeStar; CA).
Bone marrow-derived DCs. BM cells were isolated from femurs and tibias, and a single-cell
suspension was prepared and cultured for 7 to 8 days in the presence of 100 ng/ml Flt3L (Amgen,
Thousand Oaks, CA, and Cell Dex Therapeutics, Needham, MA), as previously described (73). The cells
were stimulated with 0.1 M CpG B 1668 (Integrated DNA Technologies, San Diego, CA), 100 ng/ml LPS,
25 g/ml poly(I · C), and 100 M loxoribine (Invivogen).
Real-time RT-PCR. Total RNA from sorted cells was extracted using RNeasy Micro kits (Qiagen) and
reverse transcribed into cDNA using Superscript III reverse transcriptase (RT) (Invitrogen). Total RNA from
spleen homogenates was extracted with RNeasy minikits (Qiagen), and 1 g of RNA was converted to
cDNA using a Moloney murine leukemia virus (MMLV) reverse transcriptase kit (Promega, Madison, WI).
cDNA quantification was performed with a real-time PCR detection system (Applied Biosystems, Carls-
bad, CA) using SYBR green PCR kits. All the genes were normalized to Gapdh as previously described (21).
For SYBR green, the following primers were used at 280 nM: Ifn 4/6/7 F, 5=-TATGTCCTCACAGCCAG
CAG-3=, and R 5=-TTCTGCAATGACCTCCATCA-3=; Ifn1 F, 5=-CTGGCTTCCATCATGAACAA-3=, and R, 5=-
GAGGGCTGTGGTGGAGAA-3=; Tnf F, 5=-CCCTCACACTCAGATCATCTTCT-3=, and R, 5=-GCTACGACGTGGG
CTACAG-3=; Il27p28 F, 5=-CTGTTGCTGCTACCCTTGCTT-3=, and R, 5=-CACTCCTGGCAATCGAGATTC-3=; Ebi3
F, 5=-ACAACTGAGCCACACTGGGCA-3=, and R, 5=-CCACACCGAGCCTGTAAGTGG-3=; LCMV GP F, 5=-CATTC
ACCTGGACTTTGTCAGACTC-3=, and R, 5=-GCAACTGCTGTGTTCCCGAAA-3=; LCMV NP F, 5=-GCATTGTCTGG
CTGTAGCTTA-3=, and R, 5=-CAATGACGTTGTACAAGCGC-3=; Il18 F, 5=-GCCTCAAACCTTCCAAATCA-3=, and
R, 5=-TGGATCCATTTCCTCAAAGG-3=; Il12p35 F, 5=-AAATGAAGCTCTGCATCCTGC-3=, and R, 5=-TCACCCTGT
TGATGGTCACG-3=; Gapdh F, 5=-TCCCACTCTTCCACCTTCGA-3=, and R, 5=-AGTTGGGATAGGGCCTCTCTT-3;
human GAPDH F, 5=-TGATGACATCAAGAAGGTGGTGAAG-3=, and R, 5=-TCCTTGGAGGCCATGTGGGCCAT-3=.
For Il6, TaqMan master mix (Applied Biosystems) was used in conjunction with the appropriate primers
and probe from the Universal Probe Library (Roche).
LCMV-specific antibody ELISAs. LCMV-specific enzyme-linked immunosorbent assays (ELISAs) were
done as we and others have previously described using antigen prepared by purifying LCMV on a
renografin gradient (17). Endpoint titers were calculated by determining the lowest dilution at which a
specific antibody was at least 2 times the standard deviation (SD) above background. For avidity assays,
an LCMV-specific Ig ELISA was performed. After incubation of serial dilutions, sera on LCMV-coated plates
were washed 3 times with 8 M urea or phosphate-buffered saline (PBS) prior to addition of a horseradish
peroxidase (HRP)-conjugated anti-mouse Ig secondary antibody (Southern Biotech, Birmingham, AL). The
percent binding was then determined as the optical density of urea (ODurea) divided by the ODPBS times
100 at a 1/4,000 serum dilution when both were detectable above baseline.
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Cytokine detection. Total IFN-I bioactivity was measured by luciferase bioassay with reference to a
recombinant mouse IFN- standard (Research Diagnostics, Concord, MA), using an L-929 cell line
transfected with an interferon-sensitive luciferase, as previously described (74). IL-27, TNF-, and IL-6
were measured by ELISA (eBioscience, La Jolla, CA).
In vitro infection. A549 cells (ATCC) were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(Lonza, Walkersville, MD, USA) supplemented with 2 mM L-glutamine, 50 U ml1 penicillin, and 50 mg
ml1 streptomycin (Gibco, Grand Island, NY, USA), plus 10% heat-inactivated fetal bovine serum (Lonza).
The cells were maintained in 175-cm2 flasks at a density of 0.5  106 to 1  106 cells ml1 in a total
volume of 30 ml. A total of 1  106 A549 cells were left untreated or pretreated for 1 h with 20 or 100
ng ml1 human recombinant IL-27 (Biolegend). The cells were subsequently infected with LCMV Cl13 at
a multiplicity of infection (MOI) of 0.05 or 0.5. After 1 day, the cells were washed with PBS and collected
in lysis buffer (Qiagen) for RNA analysis.
Statistics. Statistical analysis was carried out using Graphpad Prism 5.0 (Graphpad, La Jolla, CA). For
comparisons between 2 groups, a nonparametric Mann-Whitney U test was performed. For comparison
of multiple groups, a Kruskal-Wallis test, followed by Dunn’s comparison test, was used. For pairwise
analysis, a Wilcoxon test was used.
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